Clinical Trial Update: Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab and erlotinib in advanced non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2022-07-12